Aura Biosciences May Offer Securities Up To $500M Aggregate; May Sell Up To $200M Common Stock Under Sales Agreement With Jefferies
- Sec Filing
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
- Sec Filing
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Aura Biosciences (NASDAQ:AURA) with a Buy and lowers the price target from $24 to $18.
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 29.73 percent. This is a 2.13 percent decrease over losses of $(0.47) per share